Vimarsana
Biggest News Aggregation in the World

Page 2 - Chip Baird News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chip Baird. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chip Baird Today - Breaking & Trending Today

Regeneron to acquire 2seventy's cell therapy pipeline - Vimarsana News

Regeneron to acquire 2seventy's cell therapy pipeline

BioPharma

Engine Capital urges 2seventy bio to appoint finance chief Baird as CEO - Vimarsana News

Engine Capital urges 2seventy bio to appoint finance chief Baird as CEO

Activist investor Engine Capital on Wednesday urged 2seventy bio to appoint its current finance chief Chip Baird as the company's chief executive officer, in a letter sent to the cell and gene...

Engine Capital pushes for changes at cancer therapy developer 2seventy bio - Vimarsana News

Engine Capital pushes for changes at cancer therapy developer 2seventy bio

(Reuters) -Activist investor Engine Capital on Wednesday sent a letter to the board of cancer therapy developer 2seventy bio, urging a board refresh a...

Source: kelo.com
Deep Genomics adds life sciences veteran as CEO to support its evolution into biopharma firm - Vimarsana News

Deep Genomics adds life sciences veteran as CEO to support its evolution into biopharma firm

Toronto-based artificial intelligence drug development startup Deep Genomics has hired Brian O’Callaghan to replace company founder Brendan Frey as CEO.

2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway - Vimarsana News

2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway

Approximately 40% workforce reduction combined with related actions expected to achieve $130+ million savings in the 2024-2025 period; projected cash runway into at least 2026 to support focus on...